Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
Launched by JONSSON COMPREHENSIVE CANCER CENTER · Sep 7, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of MRI called multinuclear metabolic MRI to improve how we diagnose and understand gliomas, which are tumors in the brain. The goal is to develop advanced imaging technology that can help detect these tumors earlier, assess their severity, and guide treatment decisions for patients who are newly diagnosed or have recurrent gliomas.
To be eligible for this trial, participants must be 18 years or older. Some groups being studied include healthy volunteers with no brain tumors, and individuals who have either newly diagnosed or recurrent gliomas that are large enough to measure (at least 1 cm in size). Participants will undergo MRI scans as part of the study, and those who are receiving immunotherapy treatment for recurrent gliomas may also be included. It's important to know that anyone who cannot safely undergo an MRI or is under 18 years old will not be eligible for this trial. Overall, this research hopes to enhance our understanding of brain tumors and improve patient care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease
- • AIM 1: Age 18+
- • AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade)
- • AIM 2: 10 IDH mutant and 10 IDH wild type gliomas
- • AIM 2: Clinically indicated for resective surgery or biopsy
- • AIM 2: Age 18+
- • AIM 2: Tumor size \> 1x1x1 cm (measurable)
- • AIM 3: Recurrent glioma enrolled in an immunotherapy trial or clinically indicated to receive immunotherapy including anti-PD1
- • AIM 3: Age 18+
- Exclusion Criteria:
- • AIM 1: Cannot safely perform an MRI
- • AIM 1: Age \< 18
- • AIM 2: Cannot safely perform an MRI or use of MRI contrast agents
- • AIM 2: Age \< 18
- • AIM 3: Cannot safely perform an MRI or use of MRI contrast agents
- • AIM 3: Age \< 18
About Jonsson Comprehensive Cancer Center
The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Benjamin M Ellingson
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials